CoreValve refutes alleged patent infringement action by Edwards Lifesciences: "We have great confidence in our technology and our legal right to develop our ReValving(R) system for treatment of patients with advanced aortic valve disease." Jacques Seguin, M.D., Ph.D., Chairman, CEO and Founder of CoreValve

Share Article

CoreValve (http://www.corevalve.com) has been informed that Edwards Lifesciences has filed a lawsuit in the United States District Court in Delaware alleging infringement of certain Edwards patents.

    CoreValve has reviewed the claims made by Edwards and believes the lawsuit is without merit. CoreValve intends to vigorously defend its intellectual property and its legal right to continue to develop and clinically evaluate its proprietary ReValving(R) System for percutaneous aortic valve replacement in high-risk patients with advanced aortic valve disease.

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving(R) System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving(R) System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at http://www.corevalve.com.

(Caution: the CoreValve ReValving(R) System will not be available in the USA for clinical trials or for sale until further notice.)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Debbie Hayes
Visit website